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Abstract 
BACKGROUND: Cervical cancer is one of the most common cancers in women worldwide, 
often associated with the infection of human papillomavirus (HPV). Toll-like receptor 8 (TLR8), a 
pattern recognition receptor, is involved in viral nucleic acid sensing. Recently TLR8 has been 
shown to be expressed in cancer cells, and it has been suggested that it may help cancer cell 
growth and tumor development. The objective of this study is to investigate the expression of 
TLR8 expression and its relationship with Bcl-2 and VEGF in cervical cancer cells.  
METHODOLOGY/PRINCIPAL: The mRNA expression levels of Bcl-2, VEGF and TLR-7,-8,-9 
in newly diagnosed cervical cancer patients were detected by quantitative real-time PCR (qRT- 
PCR). Epifluorescence microscope was used to determine the presence of TLR8 protein in Hela 
cells. The cell cycle and apoptosis were analyzed by flow cytometer, and the cell proliferation was 
measured by MTT assay. Our data showed the increased mRNA levels of TLR8 in human cervical 
cancer samples as well as in HeLa cells, a cell line derived from a human cervical cancer. In addition, 
there was a positive correlation between the expression levels of TLR8 and Bcl-2 and VEGF in 
cervical cancer patients. When Hela cells were treated with TLR8 agonist CL075, the percentage 
of cells in G2/M +S was remarkably increased, accompanied by increased COX-2, BCL-2 and VEGF 
mRNA levels.  
CONCLUSIONS/SIGNIFICANCE: The mRNA expression level of TLR8 in the patients with 
cervical cancer and Hela cells were up-regulated, it consistent with the increased expression of 
VEGF and Bcl-2. The results suggest that TLR8 may be an interesting therapeutic target in cervical 
cancer. 
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Introduction 
Cervical cancer is the third most common cancer 
in women worldwide, with 85% of cases occurring in 
developing countries. In China, it is estimated that 
131,500 new cervical cancer cases occur annually, 
representing approximately one fifth of cases world-
wide. Human papillomavirus (HPV) infection plays a 
crucial role in the development of cervical lesions and 
tumors [1-4]. HPV is detected in almost 100% of 
women with invasive cervical cancer; and infection 
with a high-risk HPV, such as the most prevalent HPV 
16 and 18 subtypes, accounts for 76.7% of cervical 
cancer cases in China. DNAs from these HPV sub-
types are frequently integrated into the host cell ge-
nomes in noninvasive squamous intraepithelial le-
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sions and squamous cell carcinomas. This integration 
is believed to be crucial in the induced expression of 
pattern recognition receptors (PRRs) for pathogen [5].  
Toll-like receptors (TLRs) are pattern recognition 
receptors that recognize conserved patho-
gen-associated molecular patterns (PAMPs). Thirteen 
genes of the TLR family have been identified in hu-
mans and mice. These genes encode proteins which 
can recognize structurally conserved molecules de-
rived from different microorganisms and activate 
immune cell responses [6-7]. TLR7 and TLR8, which 
detect viral single stranded (ss) RNA, and TLR9, 
which detects double stranded (ds) DNA, are located 
in the endosome [1-2]. TLRs are present in dendritic 
cells, macrophages, natural killer cells and other im-
mune cells, and they have been identified as key 
components of the pathogen recognition process in 
human inflammatory responses including innate and 
adaptive immunity. In recent years, it has been found 
that TLRs are not only expressed in immune cells, but 
also in tumor cells [8]. The role of TLRs expression in 
tumor cells and its relationship with tumor develop-
ment become a new research focus in tumor immun-
ity. For example, Cherfils-Vicin et al. showed that 
TLR7 and TLR8 were expressed in human lung cancer 
cells, and loxoribine (TLR7 ligand) or PolyU (TLR8 
ligand) can up-regulate B-cells lymphoma-2 (Bcl-2) 
and promote the survival of lung cancer cells [9].  
Proteins of the Bcl-2 family regulate the apopto-
sis pathway and autophagy. The dysregulation of 
apoptosis is a key step in developing cancers, and 
mediates resistance to cancer therapy. Dysregulation 
of Bcl-2 family has been demonstrated in a wide 
spectrum of human cancers. Therefore, targeting the 
Bcl-2 family of proteins represents a promising ther-
apeutic approach for malignancies. VEGF is the most 
potent angiogenic factor in tumour angiogenesis. A 
lot of studies have suggested that vascular endothelial 
growth factor (VEGF) expression in tumour tissue is 
significantly correlated with microvessel density and 
poor prognosis in human cancers including cervical 
cancer. Our current study aims to determine the level 
of TLR8 expression in the patients with cervical cancer 
and Hela cells, and to examine the relationship be-
tween TLR8 and Bcl-2 or VEGF expression in the de-
velopment of cervical cancer. 
Materials and Methods 
Patients and healthy controls 
The cancer tissues from fifteen newly diagnosed 
cervical cancer patients were used in the current 
study. These patients ranged from 36 to 75 years of 
age (average age, 47 years). Ten cervical tissues from 
cervical biopsy patients without cancer nor endome-
triosis, age ranged from 34 to 65 years (average age, 46 
years) were used as the controls. No subject was 
treated preoperatively or had a history of autoim-
mune disease, and no control had a prior history of 
cancer. This study was approved by the research eth-
ics committee of the Affiliated Hospital of Jiangsu 
University, and written informed consent was ob-
tained from all individuals.  
Reverse transcription-PCR (RT-PCR) and 
quantitative real-time PCR (qRT- PCR) 
RNA samples were extracted from cancer or 
control specimen using TRIzol (Invitrogen Life Tech-
nologies, California, USA), total RNA was isolated 
and reversed-transcribed with ReverTra Ace 
qPCR-RT kit (TOYOBO, Osaka, Japan) according to 
the manufacturers’ instructions. RT-PCR and qRT- 
PCR were performed as described previously [10]. 
The sequences for the primers used were: β-actin, 
5’-CACGAAACTACCTTCAACTCC-3’ (forward), 
5’-CATACTCCTGCTTGCTGATC -3’ (reverse); TLR7, 
5’-CCTTTCCCAGAGCATACAGC-3’ (forward), 
5’-GGACAGAACTCCCACAGAGC-3’ (reverse); 
TLR9, 5’-GGACCTCTGGTACTGCTTCCA-3’ (for-
ward), 5’-AAGCTCGTTGTACACCCAGTCT-3’ (re-
verse); TLR8, 5’-CAGAGCATCAACCAAAGCAA-3’ 
(forward), 5’-GCTGCCGTAGCCTCAAATAC-3’ (re-
verse); COX-2, 5’-CGAGGTGTATGTATGAGTGTGG
GAT-3’ (forward), 5’-CCTTGAAGTGGGTAAGTATG
TAGTG-3’ (reverse); Bcl-2, 5’-TCCATGTCTTTGGAC
AACCA-3’ (forward), 5’-CTCCACCAGTGTTCCCAT
CT-3’ (reverse); VEGF, 5’-AGGAGGGCAGAATCAT
CACG-3’ (forward), 5’-CAAGGCCCACAGGGATTT
TCT-3’ (reverse). Relative quantification of mRNA 
expression was calculated by the comparative thresh-
old cycle (Ct) method. 
Cell culture and flow cytometry  
Hela cell, a kind of human cervical carcinoma 
cell line preserved in our laboratory, was cultured in 
DMEM medium, supplemented with 100 U/ml peni-
cillin, 100 mg/L streptomycin and 10% FBS (GIBCO, 
California, USA). For analyzing the effect of TLR8 
agonist on cell cycle, 1×106 cell suspensions were 
stimulated by CL075 (a thiazoloquinoline compound, 
used as TLR8 agonist) in different concentrations as 
indicated. After 24h treatment, the cells were collected 
by centrifugation at 4℃, 1000 r/min for 10 min. The 
cells were washed twice with PBS, and fixed with 70% 
cold ethanol at 4℃overnight followed by digestion 
with 0.2 mg/ml of RNaseA for 30 min. Flow cytome-
try was performed using FACSCalibur Flow Cytom-
eter (Becton Dickinson, Sparks, MD, USA) following 
PI staining. Apoptosis was analyzed under the similar 
conditions. In briefly, 1×105 cells were incubated with 
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CL075 at 37℃ for 48h, and stained by PI for flow cy-
tometry analysis.  
Immunofluorescence 
5×104 cells inoculated on coverslip were washed 
twice with PBS and fixed with 4% paraformaldehyde 
at 37°C for 1h. Triton-X100 was added for rupture 
membrane at room temperature for 30 min. The co-
verslip was then immersed in blocking buffer with 3% 
BSA for 60 min. TLR8 antibody (Abcam Company, 
Britain) was applied for 2h at room temperature. After 
washing, PE-labeled goat anti- mouse IgG (MultiSci-
encesBiotechCo., Ltd, China) was added at 37°C for 45 
min, followed Hochest 33258 staining at 37°C for 15 
min. The cells were examined with a fluorescence 
microscope (Olympus BX51, Tokyo, Japan) and ana-
lyzed using the Image J software.  
Cell Proliferation Assay 
Cells were seeded into 96-well plates at 1×105 
cells/ml (2×104 cells per well) and cultured for 3h at 
37°C in an air 5% CO2 atmosphere. After the cells at-
tached to the plate, CL075 in final concentration of 
0.1µg/ml, 0.5µg/ml, 1.0µg/ml or 2.5µg/ml was re-
spectively added to the wells; the cells were incubated 
at 37°C for 24h, 48h, or 72h, respectively. At each time 
point, 20 μL (5 mg/mL) of MTT (Sigma, USA) was 
added to each well, and the plate was further incu-
bated for 4 h to deoxidize MTT under light-blocking 
condition. After removal of the MTT dye solution, 
cells were treated with 150 μL DMSO, and the ab-
sorbance at 490 nm was measured using ELX 800 UV 
reader (BioTek, Winooski, VT, USA). This cell prolif-
eration assay was performed in triplicate, and re-
peated at least twice. 
Statistical analysis 
Data were expressed as the mean±SD. Statistical 
analysis was performed using Prism5 (GraphPad 
Software). All experiments were performed at least in 
twice. Statistical differences between groups were 
compared by one-way analysis of variance followed 
by Dunnett’s multiple comparison tests to identify 
significantly different results. Pearson method was 
used for correlation analysis. P values less than 0.05 
were considered significant. 
Results 
Expression of TLR8 in human cancer cell lines  
Thirteen human cancer cell lines, including 95D, 
HepG2, NICH446, U266, SGC, HCT-8, BGC, SW620, 
A549, HT1080, SKOV-3, U937 and Hela were exam-
ined for TLR8 expression. Our data showed that 
SKOV-3, U937 and Hela expressed TLR8 mRNA at 
high levels. Low TLR8 levels were found in SGC, 
HCT-8, BGC, SW620, A549 and HT1080; but no TLR8 
mRNA was detected in 95D, HepG2, NICH446 or 
U266 (Figure 1). The expression level of TLR8 mRNA 
in Hela cell line was higher than that in the other cell 
lines (Figure 1). Consistently, immunostaining 
showed presence of TLR8 protein in Hela cells (Figure 
2A).  
 
 
Fig.1 The expression of TLR8 in various human cancer cell lines. The levels of TLR8 mRNA in 13 human cancer cell lines were detected by qRT-PCR. A: Relative TLR8 
mRNA levels in each cell line as determined by qRT-PCR. B: RT-PCR product of TLR8 from Hela cells on agarose gel. Lane 1, DNA marker DL2000, Line 2, the PCR product of 
TLR8. C: RT-PCR products of TLR8 in 13 human cancer cell lines. Line 1, DNA marker DL2000; Line 2, positive control; Line 3 to Line15, U937, SGC, HCT-8, BGC, SW620, 
A549, Hela, HT1080, SKOV-3, 95D, HepG2, NICH446 and U266; Line 16, negative control. 
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Fig.2 Intracellular localization of TLR8 and the effect of CL075 stimulation in Hela cells. A: Immunostaining showed presence of TLR8 protein in Hela cells. It is 
suggestive that TLR8 protein exists in the cytoplasm of Hela cells. B: The cell cycle profiles of Hela cells after CL075 treatment determined by flow cytometry. The top three 
panel shows the cell cycle profiles of cells treated with different concentration of CL075 as indicated; the lower panels shows the effect of blank control or DDP treatment. C: 
The changes in cell cycle population after CL075 treatment of Hela cells. D: The time-course effects of CL075 on the cell proliferation in Hela cells. *P<0.05. 
 
The effect of TLR8 agonist CL075 on Hela cells 
CL075, a thiazoloquinoline compound, used as 
TLR8 agonist. Treatment of HeLa cells with CL075 for 
48h resulted increases in the percentage of G2/M+S 
phase, suggesting an increase in cell proliferation 
(Figure 2B and 2C). This was confirmed by MTT assay 
(Figure 2D). Unlike DDP, CL075 did not induce 
apoptosis in Hela cells (Fig.2B). The levels of COX-2, 
BCL-2, and VEGF mRNA was significantly increased 
after CL075 treatment for 24h, and reached to peak at 
48h in Hela cells (Figure 3).  
Enhanced expression levels of TLR7 and TLR8 
in cancer tissues from patients with cervical 
carcinoma 
Quantitative RT-PCR showed higher mRNA 
levels of TLR7 and TLR8 in cervical cancer samples 
from patients than that in cervical tissues from pa-
tients without cancer. In contrast, there was no clear 
difference in TLR9 expression in tissue samples from 
the cancer patients and controls (Figure 4). Bcl-2 and 
VEGF expression levels were significantly increased 
in cancer tissues from the patients with cervical cancer 
(Figure 4).  
Correlation analysis between TLR8 and Bcl-2 
or VEGF expression in cancer tissues  
Using the method of Spearman analysis, we 
found that there was a positive correlation between 
the expression level of TLR8 and Bcl-2 or VEGF in 
cervical cancer samples. No correlation was found 
between the TLR7 and Bcl-2 or VEGF mRNA (Figure 
5). 
Discussion 
TLRs play an important role both in innate and 
adaptive immune response, they express in dendritic 
cells, macrophages, natural killer and other immune 
cells to recognize pathogenic microorganisms and 
damaged cells, and contribute to anti-infective or an-
ti-tumor effects [11-12]. However, recent studies re-
vealed that tumor cells can also express TLRs. 
TLRs-expressed tumor tissues and cells not only hin-
der the infiltration of immune cells, but also can 
change the type of inflammation, therefore facilitate 
tumor occurrence and development [13]. The role of 
TLRs expressed in tumor cells has become a new re-
search focus in tumor immunity [14-16]. The potential 
for developing new cancer treatments is stated that 
TLR7 or TLR8 agonist, is approved for treatment of 
genital warts and has been suggested for treatment of 
other HPV-associated disease including papilloma-
virus infection [1, 17-18]. Recent studies show that 
TLR7 and TLR8 are expressed in human lung cancer 
cells, TLR7 ligand (loxoribine) and TLR8 ligand 
(PolyU) are able to up-regulate Bcl-2 expression and 
to promote the survival of lung cancer cells [2]. In this 
study, we also found increased expressions of TLR7 
and TLR8 in cervical cancer cells, suggesting that the 
TLRs mediated tumor immunity function was com-
promised in these cancer patients.  
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Fig.3. Expression of COX-2, Bcl-2 and VEGF in CL075-treated Hela cells. The mRNA levels of COX-2, Bcl-2 and VEGF in CL075-stimulated human cervical carcinoma 
cell line were detected by qRT-PCR. These data were expressed as means ± SD of three independent experiments. *P<0.05, ** P<0.01. 
 
Fig. 4. The expression of TLR7/8/9, Bcl-2, and VEGF mRNA in cervical cancer tissues. The mRNA levels of TLR7/TLR8/TLR9 and Bcl-2/VEGF in cervical cancer 
tissues from patients were analyzed by qRT-PCR. The data are expressed as means ± SD of three independent experiments. *P<0.05, ***P<0.001. 
 
Fig. 5 The correlation between TLR8 and Bcl-2/VEGF mRNA level in cervical cancer tissues from patients. The correlation between TLR7/TLR8 and Bcl-2/VEGF 
mRNA level in cervical cancer tissue was analyzed with Pearson method. A: The positive correlation was found between TLR8 and Bcl-2 expression (r=0.81, P＜0.001); B: The 
correlation between TLR8 and VEGF expression (r=0.62, P＜0.05); C: The correlation between TLR7 and Bcl-2 (r=0.07, P=0.81); D: The correlation between TLR7 and VEGF 
(r=-0.21, P=0.44). 
 
The Bcl-2 gene product is thought to contribute 
to oncogenesis by suppressing signals that induce 
apoptotic cell death, and a lot of studies have sug-
gested that VEGF expression is significantly corre-
lated with poor prognosis in human cancers [19]. In 
the present study, these two genes were selected, aims 
to analyze the expression of TLR8 in human cervical 
cancer biopsies and a possible correlation with tumor 
associated genes and evaluate the possible develop-
ment trends of cervical cancer. We observed a positive 
correlation between TLR8 expression and Bcl-2 or 
VEGF expression in cervical cancer tissues and Hela 
cells. VEGF and Bcl-2 have been shown to play im-
portant roles in angiogenesis, a critical feature for 
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tumor development. A recent report found that Bcl-2, 
as an inhibitor of apoptosis, had prognostic value in 
classical Hodgkin lymphoma [20]. The predominant 
regulator of tumor angiogenesis is VEGF, which has 
become an important target in the development of 
novel anti-tumor strategies [21-22], although the clin-
ical effectiveness of these new strategies remains to be 
seen [23]. The increased VEGF and Bcl-2 expression 
reported here suggests that future therapeutic ap-
proaches targeting on angiogenesis can be used in 
cervical cancer patients.  
Similar to human primary cervical cancer sam-
ples, the human cervical carcinoma cell line Hela also 
expressed high levels of TLR8, Bcl-2, and VEGF, 
therefore could be used as an excellent model to in-
vestigate the functions and mechanisms of TLR in 
cervical cancer cells. Our data showed that the per-
centage of cell in G2/M+S had a remarkably en-
hancement in Hela cells after treatment of CL075, a 
TLR8 ligand, indicating that the binding of TLR8 to its 
ligand stimulated cell proliferation. Furthermore, an 
increased expression of COX-2, BCL-2 and VEGF 
mRNA was observed in CL075 treated Hela cells, 
suggesting the activation of angiogenesis and inhibi-
tion of apoptosis, all of which may contribute to tu-
mor development.  
In conclusion, our data offer the convincing ev-
idence for first time that the TLR8 mRNA was upreg-
ulated both in cervical cancer tissues and Hela cells, it 
consistent with the increased expression of VEGF and 
Bcl-2 which correlated with poor prognosis in human 
cancers. Our study reveal that the high 
TLR8-expressed cervical cancer cells may strongly 
correlate with carcinogenesis and tumor invasion by 
inhibiting TLR8 positive immune cells to recognize 
tumor or viral antigen, which influenced anti-tumor 
immune response. Further investigations of its roles 
and mechanisms will provide critical information not 
only to help understand cervical cancer pathogenesis, 
but also useful for the future development of novel 
targeted therapeutic strategies. For example, it will be 
important to investigate whether TLR8 antagonists 
can affect cervical cancer cell proliferation and in vivo 
tumor growth. Our further studies will focus on the 
exploration of TLR8 in intraepithelial lymphocytes 
and tumor macrophages using stratifying samples 
with different cervical cancer grades. In short, under-
standing the functions of TLRs in cancer patient will 
be important for the developing new cancer immu-
notherapies.  
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